{'breast cancer': {'bisphosphonates': 1, 'denosumab': 1, 'actinomyces': 4, 'chemotherapy': 46, 'estradiol': 6, 'testosterone': 1, 'progesterone': 1, 'akt inhibitor': 1, 'paclitaxel': 8, 'foundationone': 1, 'pupose': 1, 'multitesting': 1, 'msh6': 1, 'msh2': 1, 'amino acid ( amino acid': 1, 'amino acid': 5, 'deregulation': 1, 'kaempferol': 1, 'ascorbic acid': 1, 'tamoxifen': 22, 'hydroethanolic': 2, 'nitric oxide': 1, 'malondialdehyde': 5, 'glutathione peroxidase ( gsh - px )': 1, 'trastuzumab': 13, 'heparin': 1, 'poloxamer': 1, 'curcuminoid': 2, 'cisplatin': 3, 'nanogels': 2, 'curcumin': 1, 'anticancer': 2, 'glutathione ( gsh )': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'doxorubicin': 8, 'ovulation': 1, 'letrozole': 12, 'clomiphene citrate': 3, 'clomiphene': 6, 'livebirth': 5, 'takeda': 1, 'roche': 1, 'estrogen receptor / progesterone receptor / human epidermal growth factor receptor': 1, 'fasting insulin': 2, 'insulin': 3, 'antineoplastic': 1, 'suramin': 3, 'suramin compound derivatives synthesized herein show potential as novel therapeutic agents for their anti - proliferative activity via': 1, 'suramin compound': 1, 'ursolic acid ( ursolic acid': 1, 'ursolic acid': 6, 'artemisinin': 1, 'dihydroartemisinin': 3, 'neoadjuvant chemotherapy': 4, 'parp inhibitor': 1, 'parp inhibitors': 1, 'tumourectomy': 1, 'hormonotherapy': 1, 'compound kushen': 2, 'chemotherapies': 1, 'nomogram': 1, 'crispr': 2, 'progesterone receptor (pr ( progesterone receptor )': 2, 'estrogen receptor': 3, 'herceptin': 14, 'dimerization blocker , stattic ( s )': 1, 'nanocarrier': 1, 'stattic': 5, 'plga nanoparticles': 1, "progesterone receptor (pr status . rates of high wilms' tumor 1-associated protein expression were 66.1": 1, 'abemaciclib': 3, 'steroid': 2, 'prednisolone': 2, 'progesterone receptor': 1, 'eribulin': 1, 'fulvestrant': 3, 'ec': 1, 'capecitabine': 1, 'docetaxel': 4, 'nivolumab': 3, 'anastrozole': 2, 'epirubicin': 5, 'cyclophosphamide': 6, 'fructose': 1, 'pertuzumab': 5, 'fluorouracil': 4, 'neosphere': 1, 'tryphaena': 1, 'imatinib': 4, 'cholesterol biosynthesis': 1, 'epoxidase inhibitors': 1, 'antifungal': 1, 'chemotherapy(tc)and': 1, 'chemo': 2, 'bevacizumab': 4, 'fulvestrant)was': 1, 'gemcitabine': 1, 'nab - paclitaxel': 1, 'icg': 1, 'intratumorally': 1, 'photodynamic': 1, 'aromatase inhibitors': 1, 'cdk4/6 inhibitors': 1, 'glucocorticoid': 1, 'anthracycline': 1, 'progesterone receptor (pr membrane component': 1, 'progesterone receptor membrane component': 7, 'fpr2': 1, 'gpr37': 1, 'ccr5': 1, 'radioactive iodine ( radioactive iodine ) treatment increased markedly . radioactive iodine': 1, 'radioactive iodine treatment': 2, 'radioactive iodine ( yes v no or unknown ) using poisson regression among > /= 5-': 1, 'radioactive iodine treatment ( 45': 1, 'nonsignificantly': 1, 'radioactive iodine': 2, 'carboplatin': 3, 'blebbing': 1, 'psychotropics': 1, 'doxycycline': 1, 'citrate ions': 1, 'anticancer compounds': 1, 'psn': 1}, 'tumor': {'folfirinox': 1, 'immunoglobulin': 1, 'methylprednisolone': 1, 'somatostatin': 1, 'bisphosphonates': 1, 'denosumab': 1, 'actinomyces': 4, 'chemotherapy': 30, 'rapamycin': 3, 'pancreaticoduodenectomy': 2, 'linifanib': 1, 'hdac': 1, 'chemo': 1, 'interleukin-2': 52, 'il-2': 48, 'docetaxel': 5, 'gemcitabine': 1, 'nab - paclitaxel against b16f10': 1, 'covalent inhibitor': 1, 'gsh': 1, 'astragalus polysaccharides': 1, 'astragalus polysaccharides )': 1, 'catla': 2, 'catla catla )': 1, 'albumin': 1, 'malondialdehyde': 1, 'glutathione peroxidase ( glutathione peroxidase': 1, 'nitric oxide synthase ( nitric oxide synthase )': 1, 'hydrogen peroxides ( h2o2 )': 1, 'astragalus polysaccharides diets on week': 1, 'astragalus polysaccharides enriched diets revealed significant improved tumor necrosis factor ( tnf)-alpha and tnf receptor - associated factor-6 ( tnf receptor-associated factor-6 ) mrna expression on week': 1, 'paclitaxel': 5, 'praziquantel': 1, 'pd-1': 1, 'pemetrexed': 1, 'cisplatin': 5, 'mek inhibitor ( mek inhibitor': 1, 'mek inhibitor / anti - pancreaticoduodenectomy - l1 therapy (pdt': 1, 'optn': 1, 'photothermal': 6, 'aecii': 1, 'spirulina': 2, 'atezolizumab': 1, 'akt inhibitor': 1, 'foundationone': 1, 'taxane': 2, 'cobas': 1, 'osimertinib': 1, 'fluorouracil': 1, 'leucovorin': 1, 'irinotecan': 8, 'oxaliplatin': 1, 'serine hydrolase carboxylesterase': 1, 'pdgfra': 1, 'kras': 2, 'braf': 2, 'nctn': 1, 'amino acid ( amino acid': 1, 'amino acid': 4, 'o2': 1, 'mineral nanomedicine': 1, 'europium - doped calcium fluoride': 1, 'electrodynamic': 2, 'zeolite imidazole': 1, 'single amino acid mutations': 1, 'mmp8': 1, 'eotaxin': 1, 'tgfrbeta': 1, 'mmp2': 1, 'phosphodiesterase-5 inhibitors': 1, 'metformin': 11, 'neoadjuvant immunotherapy': 1, 'nivolumab': 1, 'ipilimumab': 2, 'pembrolizumab': 5, 'beta - hydroxybutyrate ( beta-hydroxybutyrate )': 1, 'fatty acid': 4, 'insulin': 3, 'beta-hydroxybutyrate': 1, 'quantitative insulin sensitivity check index rquicki - beta-hydroxybutyrate': 1, 'suvmean': 1, 'kaempferol': 1, 'ascorbic acid': 1, 'fatty acids': 1, 'hexadecenoic acid': 1, 'il-2 hydroxy octadecanoic acid': 1, 'dienes': 1, 'phytosphingosine': 1, 'doxorubicin': 1, 'ceramide b ( 2 )': 2, 'sertoliomas': 1, 'aprepitant': 1, 'clinicopathological': 2, 'heparin': 1, 'poloxamer': 1, 'curcuminoid': 2, 'nanogels': 2, 'curcumin': 1, 'annexin': 1, 'p38 inhibitor': 1, 'jnk inhibitor': 1, 'pklr': 1, 'furosemide': 3, 'cimetidine': 2, 'para - amino hippuric acid': 1, 'saline': 1, 'oat inhibitor': 1, 'superoxide dismutase': 1, 'lavage': 3, 'conatumumab': 1, 'quercetin': 1, 'glucocorticoid receptor interactions in normal tissues and tumor is crucial': 1, 'glucocorticoid receptor antagonists ru486 ( mifepristone )': 1, 'dexamethasone': 1, 'antagonist': 1, 'glucocorticoid receptor interactions can be measured in vivo with (': 1, 'glucocorticoid receptor antagonists': 1, 'c5ar antagonist blocked': 1, 'ductal': 2, 'acinar': 1, 'clonally': 1}, 'cancer': {'urapidil': 1, 'bisphosphonates': 1, 'denosumab': 1, 'actinomyces': 4, 'chemotherapy': 26, 'intratumoral': 1, 'corynoline': 1, 'acetylcorynoline': 2, 'rapamycin': 4, 'mercapturic acid': 1, 'multivalency': 1, 'linifanib': 1, 'cytosponge': 1, 'rosetrees': 1, 'stoneygate': 1, 'cisplatin': 10, 'gemcitabine': 9, 'pemetrexed': 2, 'bevacizumab': 1, 'demethylase': 6, 'higenamine': 1, 'hdac': 1, 'magl': 1, 'pharmacokinetics': 1, 'chemoradiotherapy': 4, 'carboplatin': 1, 'paclitaxel': 6, 'trametinib': 2, '-1/1/2/3': 1, 'pd-1 monoclonal antibody treatment . collectively , these data demonstrate that ifitm4p may serve as a new therapeutic target in blockage of oral': 1, 'pd-1 monoclonal antibody can be an efective reagent': 1, 'chemo': 1, 'docetaxel': 5, 'nab - paclitaxel against b16f10': 1, 'paeoniaceae': 1, 'p70s6 k signaling': 1, 'imidazoquinoline agonists': 1, 'covalent inhibitor': 1, 'gsh': 1, 'cytotoxic': 1, 'photothermal': 4, 'iron oxide': 1, 'chemotherapies': 1, 'chloroisopropyl': 2, 'phosphate': 1, 'organophosphate': 1, 'mek inhibitor ( mek inhibitor': 1, 'mek inhibitor / anti - pd - l1 therapy (pdt': 1, 'optn': 1, 'chemokine ligand': 1, 'lr': 1, 'rbc folate': 3, 'rbc': 1, 'rbc folate concentration': 1, 'normal folate status is important for reducing the risk of cervical intraepithelial': 1, 'propofol': 4, 'sevoflurane': 2, 'anesthesia': 1, 'icnb': 3, 'asa': 1, 'anesthetics': 1, 'estradiol': 1, 'testosterone': 1, 'progesterone': 1, 'nicotine': 2, 'imatinib': 3, 'erlotinib': 1, 'nilotinib': 1, 'dasatinib': 3, 'sorafenib': 1, 'scopolamine': 1, 'allyl isothiocyanate ( allyl isothiocyanate )': 1, 'allyl isothiocyanate': 4, 'allyl isothiocyanate action': 1, 'intragastrically': 1, 'irrespectively': 1, 'allyl isothiocyanate considerably lowered thyroid hormones ( ft4 , ft3 )': 1, 'allyl isothiocyanate at': 2, 'hydroxybutyric acid': 1, 'insulin': 1, 'blood insulin': 1, 'atezolizumab': 1, 'nomogram': 1, 'akt inhibitor': 1, 'foundationone': 1, 'taxane': 2, 'cobas': 1, 'osimertinib': 1, 'pupose': 1, 'multitesting': 1, 'msh6': 1, 'msh2': 1, 'nctn': 1, 'amino acid ( amino acid': 1, 'amino acid': 1, 'anticoagulation': 1, 'glyco disulfide acted as reducing and capping agents of gold ions': 1, 'o2': 1, 'crispr': 1, 'phosphodiesterase-5 inhibitors': 1, 'metformin': 11, 'lewis acid as additive': 1, 'trifluridine': 2, 'tipiracil': 2, 'ftd': 1, 'fluorouracil': 2, 'deregulation': 1, 'oxaliplatin': 3, 'supplementation': 1, 'ceramides': 1, 'fdi': 1, 'neoadjuvant immunotherapy': 1, 'nivolumab': 1, 'ipilimumab': 2, 'ccrt': 1, 'iqr': 2, 'pembrolizumab': 5}, 'tumors': {'somatostatin': 1, 'epoetin alpha ( retacrit(r ) )': 1, 'chemotherapy': 26, 'iron': 2, 'epoetin': 1, 'epoetin alpha biosimilar were reported': 1, 'intratumoral': 2, 'antibiotics': 1, 'diuretics': 1, 'cisplatin': 8, 'biotherapeutic cocktail': 1, 'hdac': 1, 'chemo': 6, 'docetaxel': 2, 'gemcitabine': 1, 'nab - paclitaxel against b16f10': 1, 'photothermal': 6, 'icnb': 3, 'asa': 1, 'anesthetics': 1, 'nomogram': 1, 'akt inhibitor': 1, 'paclitaxel': 14, 'foundationone': 1, 'pdgfra': 1, 'amino acid ( amino acid': 1, 'amino acid': 3, 'o2': 1, 'phosphodiesterase-5 inhibitors': 1, 'trifluridine': 2, 'tipiracil': 2, 'ftd': 1, 'fluorouracil': 2, 'pembrolizumab': 7, 'ipilimumab': 1, 'phosphatidic acid': 1, 'cholesteryl esters distinguished amino acid': 1, 'sertoliomas': 1, 'chemoradiation': 1, 'aprepitant': 1, 'biocompatible iron oxide nanoparticle': 1, 'iron oxide': 2, 'iron oxide nanomaterials': 1, 'furosemide': 3, 'cimetidine': 2, 'para - amino hippuric acid': 1, 'saline': 1, 'oat inhibitor': 1, 'carboplatin': 2, 'albumin': 1, 'isoniazid': 1, 'rifampin': 1, 'premetrexed': 1, 'ductal': 2, 'acinar': 1, 'clonally': 1, 'overexpressing': 1, 'uracil': 1, 'doxorubicin': 8, 'cytarabine': 1, "1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide ( 1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide )": 1, "1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide": 1, 'oxaliplatin': 7, 'liposomal oxaliplatin': 1, 'shrewd immunohistochemical': 1, 'anisole': 1, 'tfeb': 3, 'alizarin red stainings': 1, 'osteopontin': 1, 'myomatous': 1, '95%ci': 1, 'intracytoplasmic': 1, 'vacuolation': 1, 'taxol': 3, 'taxane': 1, 'kirsten rat sarcoma viral oncogene proto - oncogene gtpase ( kirsten rat sarcoma viral oncogene )': 1, 'ameloblastomas': 2, 'unerupted': 2, 'steroid hormone biosynthesis , bile acid biosynthesis': 1, 'estrogen biosynthesis': 1, 'heterotypic': 1, 'palisading': 1, 'histopathological': 1, 'crispr': 1, 'tetracycline': 1, 'doxycycline': 1, 'cox-2': 1, 'microsomal prostaglandin e': 1, 'ptges': 3, 'azoxymethane': 1, 'dextran sodium sulfate': 1, 'mpges-1': 2, 'methylprednisolone': 1, 'steroids': 1, 'immunosuppressants': 1}, 'polycystic ovarian syndrome': {'ovulation': 1, 'letrozole': 27, 'clomiphene citrate': 7, 'clomiphene': 23, 'livebirth': 5, 'takeda': 1, 'roche': 1, 'folic acid': 1, 'folic acid (pfhxs , and a control group ( group 3': 1, 'folic acid (pfhxs from 1 month': 1, 'ampk': 1, 'insulin': 68, 'impaired insulin secretion': 1, 'metformin': 58, 'normal saline water ( 0.9': 1, 'malondialdehyde': 3, 'choline': 3, 'omega-3': 2, 'omega-3 ( 10.78 + /- 1.71 )': 1, 'estradiol': 13, 'progesterone': 15, 'gpx3': 1, 'tamoxifen': 3, 'glucose': 2, 'ellagic acid treatment restored them to levels seen in the control group . ellagic acid reduced the days': 1, 'dehydroepiandrosterone': 5, 'estrogen receptor (lhr ( estrogen receptor )': 1, 'ellagic acid treatment': 1, 'ellagic acid improved glucose intolerance and insulin intolerance': 1, 'ellagic acid groups': 1, 'ellagic acid': 4, 'carbamazepine': 1, 'ovarian insulin resistance in polycystic ovarian syndrome remain elusive . methods : follicular fluid': 1, 'vitamin d': 6, 'antimullerian hormone (fsh levels , antral follicle': 1, 'luteinizing hormone (fsh / choriogonadotropin receptor (lhr ; cyp17a1 : cytochrome p450 family 17 subfamily a member': 1, 'fasting insulin ( fins : wmd -3.40': 1, 'lithium': 4, 'steroid hormone (fsh profiles were compared between patients with and without follicle-stimulating hormone receptor - autoantibodies or luteinizing hormone receptor - autoantibodies . signal linearity and detection ranges were characterized and both methods': 1, 'steroid': 8, 'hirsuitism': 1, 'scopus': 1, 'embase': 1, 'lkb1': 1, 'rapamycin': 10, 'ventriculo': 1, 'superoxide dismutase ( superoxide dismutase )': 2, 'papash': 1, 'gsh': 1, 'cinahl': 2, 'amino acid (pfhxs residues crucial': 1, 'shrna': 1, 'aspirin': 1, 'nonsteroidal': 1, 'hyperandrogenism': 2, 'sildenafil': 1, 'diuretics': 1, 'diuretic': 1, 'anorexigenic': 1, 'serum insulin': 5, 'steroidal hormones': 1, 'luteinizing hormone': 3, 'anethum': 1, 'kurz': 1, 'tilatailam': 3, 'gonadotropins': 1, 'clomiphene citrate ( clomiphene citrate': 2, 'fibroscan': 1, 'fasting insulin': 1, 'acetylcysteine': 1, 'antioxidants': 1, 'cv-6': 1, 'sp-6': 1, 'body insulin sensitivity measured by the clamp': 1, 'chemerin': 4, 'normal progesterone secretion with lower concentrations in polycystic ovarian syndrome human luteinised granulosa cells': 1, 'unani': 1, 'lashansky': 1, 'sportdiscus': 1, 'rat': 1, 'sf': 4, 'aromatase inhibitors ( aromatase inhibitors )': 1, 'aromatase inhibitors': 3, 'aromatase inhibitors treatment . polycystic ovary syndrome ( polycystic ovarian syndrome )': 1, 'chemotherapy': 2, 'herbicides': 1, 'oestrogen': 1, 'masashi': 1, 'curcumin': 6, 'oogenesis': 1, 'intracytoplasmic sperm injection': 1, 'kisspeptin hormone (fsh - release kinetics . it highlighted the recently identified ligands': 1, 'pioglitazone': 1, 'nitric oxide': 3, 'dehydroepiandrosterone - sulfate': 1, 'vitamin d supplementation': 1, 'perfluorooctanesulfonic acid )': 1, 'perfluorohexane sulfonic acid': 2, 'genistein': 6, 'estrogen receptor': 1, 'exaggerated insulin': 1, 'progesterone metabolite allopregnanolone ( allopregnanolone )': 1, 'benzodiazepines': 1, 'sepranolone': 1, 'probiotics': 2, 'synbiotics': 1, 'parasitome': 1, 'ellagic acid (pfhxs ( ellagic acid )': 1, 'cholesterol': 1, 'ellagic acid ( p < 0.05 )': 1, 'ellagic acid supplementation can be helpful as a diet supplement in women with polycystic ovarian syndrome through improvement in insulin resistance': 1, 'statin': 1, 'blood glucose': 1, 'statins': 1, 'acarbose': 1, 'myoinositol': 1, 'aucglucagon': 1, 'valproate': 3, 'lamotrigine': 6, 'ld)-vpa': 1, 'tpa': 1, 'spironolactone': 5, 'f1 formulation': 1}, 'gejc': {'trifluridine': 2, 'tipiracil': 1, 'ftd': 8, 'nivolumab': 12, 'lapatinib': 2, 'everolimus': 1, 'pertuzumab': 4, 'chemotherapy': 51, 'olaparib': 1, 'apatinib': 5, 'vegfr tyrosine kinase inhibitor': 1, 'camrelizumab': 3, 'neoadjuvant immunotherapy , of cohort 2 is 2 - year complete response rate (dcr , defined as absence of macroscopic or microscopic residual disease ( locally / regionally / distantly )': 1, 'ipilimumab': 1, 'nivo': 1, 'moutafi': 1, 'mgejc': 1, 'ramucirumab': 1, 'pembrolizumab': 4, 'dual blockade': 1, 'oxaliplatin': 2, 'platinum chemotherapy': 1, 'immunomodulation': 2, 'chemo': 1, 'tgfbeta': 1, 'bintrafusp alfa': 2, 'trastuzumab': 5, 'capecitabine': 1, 'cisplatin': 1, 'immunohistochemical': 1, 'pharmacokinetics': 5, 'neoadjuvant chemotherapy': 1, '46,501': 1, 'akt inhibitor': 1, 'potentiate': 1, 'ipatasertib': 2, 'leucovorin': 1, 'infusional': 1, 'paclitaxel': 1, 'irinotecan': 1, 'avelumab': 1, 'durvalumab': 1, 'atezolizumab': 1}, 'toxicity': {'insulin': 1, 'hoxy)phenoxy)acetic acid ( lead compound': 1, 'intraperitoneally': 1, 'mercapturic acid': 1, 'quercetin': 6, 'pb+ quercetin group was fed with ration supplemented': 1, 'blood urea nitrogen ( blood urea nitrogen': 1, 'quercetin supplementation': 4, 'pb': 5, 'malondialdehyde': 11, 'glutathione peroxidase': 1, 'hdac': 1, 'analgesic': 1, 'anesthetics': 1, 'isoflurane': 3, 'stereological': 1, 'methylimidazolium nitrate': 1, 'gossypium': 1, 'dreg': 2, 'antibiotic': 6, 'coelomocytes': 1, 'aromatic amino acids )': 1, 'sulfonamides ( sulfonamides )': 1, 'sulfonamides': 1, 'ecotoxicity': 1, 'antibiotics': 4, 'sulfadiazine': 1, 'sulfamethoxazole': 1, 'sulfamethazine': 1, 'arsenic trioxide ( arsenic trioxide )': 1, 'arsenic trioxide': 2, 'rapamycin': 1, 'antimalarials': 1, 'sixteen compounds': 1, 'carbamazepine': 1, 'ibuprofen': 3, 'triclosan': 1, 'antifungal': 1, 'zinc': 1, 'chlorobutanol': 5, 'cadmium': 2, 'imatinib': 3, 'erlotinib': 1, 'nilotinib': 1, 'dasatinib': 3, 'sorafenib': 1, 'amiodarone': 1, 'diclofenac': 3, 'transcriptomics': 1, 'ciguatoxin': 1, 'lactobacillus': 1, 'bifidobacterium': 1, 'fumonisin': 9, 'intragastrically': 1, 'platelets': 1, 'necroinflammation': 1, 'fumonisins': 1, 'metformin': 6, 'fluoroquinolone': 2, 'ciprofloxacin': 8, 'cometabolism': 1, 'mineral nanomedicine': 1, 'europium - doped calcium fluoride': 1, 'carbapenems': 1, 'chemotherapy': 30, 'trifluridine': 2, 'tipiracil': 2, 'ftd': 1, 'fluorouracil': 2, 'oxaliplatin': 10, 'amenability': 1, 'phosphatidylcholine': 1, 'cpx': 1, 'sphma7': 1, 'helichrysum': 1, 'peganum': 1, 'ellagic acid derivatives ( 3 ,': 1, 'gallic acid derivatives ( 5 ,': 1, 'phosphofructokinase': 1, 'admet': 1, 'mvocs': 2, 'ganoderma': 1, 'nitric oxide': 1, 'amino acid residues': 1, 'ericaria': 2, 'linoleamide': 1, 'palmitamide': 1, 'oleamide': 1, 'erucamide': 1, 'folin': 1, 'anticancer': 4, 'antifouling compounds': 1, 'red alga sphaerococcus coronopifolius': 2, 'bromosphaerol': 4, 'calcium salts': 1, 'levulinic acid': 2, 'calcium carbonate': 1, 'murashige': 1, 'analogs': 2, 'tansy': 1, 'mirtazapine': 7, 'potassium dichromate (': 1, 'selenium': 4, 'il-2': 1, 'cbd2': 1, 'celluclast': 1, 'faggion': 1, 'alectinib': 2, 'carboplatin': 1, 'cbdca': 3, 'cisplatin': 5, 'aprepitant': 1, 'docetaxel': 4, 'nanosponges': 1, 'dexamethasone': 4, 'antifouling': 1, 'antifouling sol - gel': 1, 'fe(iii': 2, 'glutathione ( gsh )': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'doxorubicin': 2, 'conatumumab': 1, 'irinotecan': 3, 'gemcitabine': 10, 'capecitabine': 5, 'pd.acute fish toxicity ( pd.acute fish toxicity )': 1, 'pure compounds': 1, 'microg': 3, 'octanol': 1, 'decanol': 1, 'bifenthrin': 1, 'caenorhabditis': 1, 'oscillospiraceae': 1, 'lachnoclostridium': 1, 'liposomal oxaliplatin': 1, 'mesalazine': 2, 'adlay': 1, 'brittanica': 1, 'gailardia': 1, 'antioxidant compounds': 1, 'free chlorine': 1, 'artemia': 1, 'lliver': 1, 'lactic acid': 1, 'methylprednisolone': 1, 'steroids': 1, 'immunosuppressants': 1, 'baclofen': 5, 'selenium ( selenium ) supplementation can restrict metal uptake by roots and translocation to shoots , which is one': 1, 'citrate': 2, 'amino acids': 1, 'subtoxic': 3, 'intracerebroventricular': 1, 'cysteine protease': 1, 'gefitinib': 7, 'pemetrexed': 1, 'hematological': 1, 'chemoradiation': 1, 'radiosensitizing': 1, 'microci': 2, 'vip152': 1, 'meclofenamate': 6, 'nonsteroidal': 1, 'copper chelating abilities': 1, 'steroid': 1, 'rifampicin': 1, 'isoniazid': 1, 'quinolone': 1, 'linezolid': 6, 'tb medicines': 1, 'honokiol': 1, 'curcumin nanoparticles ( curcumin - nanoparticles ) against copper oxide nanoparticle ( cuo - np)-mediated hepatorenal effects on behavioral performance , biochemical markers , antioxidants , inflammation , apoptosis , and histopathology in rats . study design : twenty wistar adult male rats were randomly divided into four groups ( n=5 )': 1, 'iotaiota': 1, 'gavaged': 1, 'curcumin - nanoparticles (': 1, 'curcumin - nanoparticles': 1, 'histopathological': 2, 'uric acid': 1, 'tamoxifen': 1, 'genistein': 1, 'apigenin': 1, 'nicotinic acetylcholine receptors': 3, 'rituximab': 1, 'cyclophosphamide': 1, 'vincristine': 1, 'prednisolone': 1, 'r - chop . methods : we developed a predictive model ( tolerability of r - chop in aggressive lymphoma [ trail ] ) on the basis of a training data set from the phase iii goya trial ( obinutuzumab with chop v r - chop in 1l diffuse large b-cell lymphoma ) using a composite binary end point , identifying patients who prematurely stopped or required reductions of r - chop . candidate predictive variables were selected on the basis of known baseline characteristics that contribute to patient frailty , comorbidity , and/or chemotherapy toxicity . trail was developed using an iterative trial - and - error modeling process to fit a logistic regression model . the final model was evaluated for robustness using a goya holdout data set and the phase iii main ( r - chop with or without bevacizumab': 1, 'spiro heterocycles were synthesized via': 1, 'isatoic anhydride': 1, 'barbituric acid / thiobarbituric acid': 1, 'etoposide': 1, 'oleic acid , tocopherol , methyl ester , diterpene alcohol , triterpene and fatty acid ester': 1, 'wasmann': 1, 'ethyl acetate': 1, 'photodynamic': 1, 'paclitaxel': 1, 'porphyrin prodrugs are synthesized': 1, 'chemo': 1, 'illudane glycosides ptesculentoside': 1, 'ptaquiloside': 2, 'nickel nanoparticles nanoparticles': 1, 'urothelial': 1, 'pembrolizumab': 1, 'enfortumab vedotin': 3, 'ghb': 8, 'exogenously': 1, 'pharmacokinetics': 1, 'gabaergic': 1, 'analogues': 1, 'herceptin': 4}, 'infertility': {'syngeneic': 1, 'taurine transporter ( taut /': 1, 'guanidinoacetic acid (gaa ( guanidinoacetic acid )': 1, 'probenecid': 1, 'estradiol': 6, 'progesterone': 8, 'progestin': 9, 'levonorgestrel': 1, 'etomidate': 4, 'analgesic': 1, 'propofol': 3, 'intraperitoneally': 1, 'detortion': 1, 'ovulation': 1, 'letrozole': 22, 'clomiphene citrate': 4, 'clomiphene': 8, 'livebirth': 5, 'takeda': 1, 'roche': 1, 'hormone agonist': 2, 'cancer': 1, 'cinahl': 1, 'amino acid (gaa sequence in testis-specific protein y-encoded 1 protein': 1, 'noninterventional': 1, 'merck': 18, 'darmstadt': 6, 'germany': 2, 'theramex': 1, 'ferring pharmaceuticals a / s , grant': 1, 'chemotherapy': 5, 'oocyte': 1, 'adalimumab': 1, 'malondialdehyde': 6, 'inactivators': 1, 'zika': 1, 'intracytoplasmic sperm injection ( intracytoplasmic sperm injection': 1, 'intracytoplasmic sperm injection': 3, 'vitamin e': 3, 'vitamin e (': 2, 'oestradiol': 1, 'endometritis': 1, 'antibiotics': 1, 'hormones': 1, 'isotretinoin': 1, 'benzodiazepines': 1, 'statins': 1, 'tetracyclines': 1, 'irisin': 1, 'thyroid replacement therapy . the association between body mass index and subclinical hypothyroidism': 1, 'sperm': 1, 'insulin': 7, 'multivitamins': 1, 'folic acid (gaa supplements': 1, 'kindara.com': 1, 'berberis': 1, 'berberine': 2, 'contraceptives': 1, 'blaschko': 1, 'circulating insulin': 1, 'metformin': 4, 'intracytoplasmic sperm': 1, 'antisperm': 12, 'gonadotropins': 2, 'aase': 1, 'ejner': 1, 'mir-193a-5p': 1, 'artificial insemination': 2, 'hsalt': 1, 'normoxia': 1, 'o2': 1, 'spermatocytes': 1, 'spermatids': 2, 'globozoospermia': 1, 'bromocriptine': 5, 'dopamine': 2, 'jinfeng': 3, 'ceftriaxone': 2, 'doxycycline': 2, 'penicillin': 2, 'moxifloxacin': 2, 'nitroimidazoles': 1, 'metronidazole': 1, 'chromatin': 1, 'fatty acid (gaa oxidation': 1, 'crispr': 1, 'cct6b': 1, 'glucose': 2, 'scopus': 1, 'embase': 1, 'bibliographies': 1, 'hydroxybutyryllysine': 1, 'lysinecrotonyllysine': 1, 'methyllysine': 1, 'kac': 1, 'lysineacetyllysine': 1, 'kpr': 1, 'normal saline water ( 0.9': 1, 'il-6': 1, 'synthetic oestrogen diethylstilbestrol ( diethylstilbestrol )': 1, 'diethylstilbestrol': 7, 'cry1': 4, 'per2': 1, 'bmal1': 1, 'ferring': 2, 'pharmasure': 1, 'bessins': 1, 'dermatomyositis': 1, 'methotrexate': 1, 'salazopyrine': 1, 'cyclophosphamide': 1, 'vitamin c ( vitamin c )': 1, 'antioxidant supplements': 1, 'vitamin c ( 600 microm )': 2, 'hyperoside': 3, 'vitamin c': 3, 'shanghai municipal science': 1, 'shanghai': 5, 'shuguang': 1, 'phosphoglycerate': 1, 'busulfan': 3, 'loboob': 3, 'genistein': 4, 'steroid': 2, 'choline': 3, 'omega-3': 2, 'omega-3 ( 10.78 + /- 1.71 )': 1, 'transmembrane protease serine': 1, 'transcriptional': 1, 'ashwagandha': 1, 'estrogen': 1}, 'gastric cancer': {'clinicopathological': 1, 'chemotherapy': 80, 'paclitaxel': 11, 'antifungal': 1, 'anticancer': 2, 'brd4': 1, 'oxaliplatin': 45, 'nivolumab': 18, 'unresectable': 4, 'steroid': 4, 'adachi': 3, 'docetaxel': 24, 'trastuzumab': 4, 'ramucirumab': 2, 'irinotecan': 1, 'capecitabine': 3, 'cisplatin': 3, 'ventriculoperitoneal': 1, 'nab - paclitaxel': 1, 'peptidyl arginine deiminase': 1, 'adjuvant chemotherapy': 1, 'trastuzumab(tmab)and': 1, 'tmab': 1, 'chemotherapy(tc)and': 1, 'chemo': 2, 'anastrozole': 1, 'bevacizumab': 1, 'fulvestrant)was': 1, 'response(cr)after': 1, 'nab - paclitaxel plus ramucirumab . the tumor marker levels decreased , the lymph nodes shrank , and pathological response was achieved again with the fourth - line treatment . the treatment is still ongoing 2 year and 8 months': 1, 'iron': 1, 'erythropoietin': 1, 'folfox': 3, 'azithromycin': 1, 'oxygen': 1, 'nab - paclitaxel plus ramucirumab , then treated with nivolumab': 1, 'fluorouracil': 20, 'leucovorin': 19, 'lcv': 1, 'histone deacetylase': 3, 'antiemetic': 3, 'doxorubicin': 4, 'cyclophosphamide': 1, 'aprepitant': 1, 'tricarboxylic acid': 1, 'dexamethasone': 1, 'ahcy': 1, 'chdh': 1, 'antimitotic chemotherapy medication': 1, 'labeled docetaxel': 1, 'alvotere': 4, 'nanoalvand': 1, 'anthracyclines': 1, 'chemotherapeutic': 1, 'mir-96': 1, 'immunoblotting': 1, 'h3 lysine 4': 1, 'h3 lysine': 1, 'actinobacteria': 1, 'leptotrichia': 1, 'lachnospiraceae': 1, 'megasphaera': 1, 'f16': 1, 'moryella': 1, 'filifactor': 1, 'deregulation': 1, 'antibiotic': 3, 'clarithromycin': 1, 'metronidazole': 1, 'levofloxacin': 1, 'amoxicillin': 1, 'hsa': 1, 'podoplanin': 1, 'circrna': 1, 'mir-637': 1, 'pepsinogen': 1, 'tff1': 1, 'amino acid residues in the saccharide primers': 1, 'amino acid selectivity': 1, 'apatinib': 1, 'pembrolizumab': 1, 'polyethylene glycol - poly(epsilon - caprolactone ) ( peg - pcl ) nanoparticles ( nanoparticles )': 1, 'alvoxal': 2, 'immunohistochemistry': 1, 'preoperative': 1, 'euro22': 1, 'lactulose': 1, 'fresh frozen plasma': 1, 'hemodiafiltration': 1, 'proquest': 1, 'probiotics': 1, 'antibiotics': 1, 'asa': 2, 'cochrane library databases': 1}, 'cardiotoxicity': {'anthracyclines': 10, 'paclitaxel': 2, 'cisplatin': 9, 'amidinourea': 2, 'r - chop regimen of pegylated liposomal': 1, 'doxorubicin': 195, 'chemotherapy': 40, 'resveratrol ( resveratrol )': 1, 'resveratrol': 3, 'antibiotic': 3, 'steroid': 2, 'diuretics': 2, 'azacitidine': 1, 'osimertinib': 4, 'oxygen': 1, 'pyroptosis': 2, 'nigericin': 2, 'calycosin': 1, 'antipyroptotic': 1, 'adenosine triphosphate': 3, 'superoxide dismutase': 2, 'anthracycline': 26, 'phthalate': 2, 'acyl hydrazine': 1, 'thiourea': 1, 'humanized monoclonal antibody': 1, 'nanoforms': 1, 'loperamide': 5, 'opioid': 3, 'methadone': 1, 'naloxone': 1, 'trastuzumab': 62, 'carboplatin': 1, 'oxaliplatin': 1, 'anticancer': 7, 'bortezomib': 6, 'normal saline': 1, 'receptor agonist': 1, 'bupivacaine': 3, 'bw373u86': 1, 'pegylated': 1, 'adriamycin': 2, 'isoproterenol': 5, 's.c': 1, 'anesthesia': 1, 'tamoxifen': 3, 'paroxetine': 3, 'lapatinib': 4, 'bcl': 1, 'cyclophosphamide': 2, 'chrysin': 1, 'malondialdehyde': 16, 'acetylcholinesterase': 5, 'chemotherapies': 1, 'imatinib': 3, 'ponatinib': 1, 'transporter inhibitors in different cell lines': 1, 'il-2': 1, 'ifngamma': 1, 'immunomodulatory monoclonal antibodies endowed with more potent anti - cancer activity on triple negative breast cancer and lower cardiotoxic side effects than the combination of atezolizumab': 1, 'ipilimumab': 4, 'fondazione italiana linfomi )': 1, 'liposomal': 1, 'doxorubicine': 1, 'reinduction': 1, 'clofarabine': 1, 'vinorelbine': 1, 'thiotepa': 1, 'loulu': 3, 'gapdh': 1, 'nicotinamide': 1, 'coumarin': 1, 'parthenolide': 1, 'ligustilide': 1, 'aihf': 2, 'arenobufagin': 9, 'analgesic': 1, 'free radicals': 1, 'dawley': 1, 'hyaluronate': 1, 'nanocarrier': 1, 'hyaluronic acid ( hyaluronic acid )': 1, 'solanesol': 1, 'hyaluronic acid': 2, 'conjugate ( hyaluronic acid - solanesyl thiosalicylate )': 1, 'hyaluronic acid - solanesyl thiosalicylate nanoparticles': 1, 'hyaluronic acid - solanesyl thiosalicylate - doxorubicin showed superior tumor inhibition compared with free doxorubicin , as well as lower cardiotoxicity and': 1, 'rvlpulse': 1, 'zebralab': 1, 'ticlopidine': 9, 'adp': 4, 'adenosine diphosphate': 1, 'astragali': 3, 'dantrolene': 6, 'calcium': 1, 'fluorouracil': 1, 'valsartan': 2, 'amlodipine': 2, 'lisinopril': 3, 'rats': 1, 'lsp': 1, 'pretreatments': 1, 'mitoxantrone': 8, 'glutathione peroxidase ( gsh - px )': 2, 'subchronic': 1, 'mtx': 12, 'disulfiram': 2, 'humanized monoclonal antibody that significantly improves metastatic and non - metastatic breast cancer therapeutic outcomes . this study compares': 1, 'crocin': 3, 'milrinone': 1, 'iii inhibitor in cynomolgus monkeys , and share': 1, 'interactions': 1, 'pd-1': 1, 'prevotellaceae': 1, 'butyrate supplementation alleviated pd-1 / pd - l1 inhibitor': 1, 'chemo': 2, 'oseltamivir': 3, 'epirubicin': 1, 'daunorubicin': 1, 'imatinib mesylate ( imatinib mesylate': 1, 'imatinib mesylate': 4, 'imatinib mesylate - treated groups . oil red o staining suggested obvious cardiac lipid accumulation after': 1, 'monoclonal antibodies': 1, 'pertuzumab': 1, 'fenitrothion': 8, 'glutathione reductase ( glutathione reductase )': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'resveratrol complexes with protein and dna sequences of sirt1 were lower than docked complexes': 1, 'neoadjuvant chemotherapy': 2, 'mangostin': 3, 'vitamin e ( 200 iu / kg )': 1, 'vitamin e ( 19 days )': 1, 'intraperitoneally': 1, 'antiinflammatory': 1, 'antiapoptotic': 1, 'catecholaminergic hormone release': 1, 'free': 1, 'dioscorea': 1, 'methotrexate': 1, 'troxerutin': 2, 'ampk': 1, 'superoxide dismutase antioxidants': 1, 'angiotensin receptor blockers (arbs ( angiotensin receptor blockers )': 1, 'beta-blockers and angiotensin-converting enzyme inhibitors / angiotensin receptor blockers': 1, 'bb': 3, 'angiotensin': 1, 'beta-blockers or angiotensin-converting enzyme inhibitors / angiotensin receptor blockers were significantly associated with higher lvefs . for anthracyclines': 1, 'quercetin ( quercetin )': 1, 'quercetin': 1, 'monotherapy': 1, 'nivolumab': 3, 'pembrolizumab': 2, 'n=39': 1, 'arachidonic acid metabolism , linoleic acid metabolism': 1, 'dox': 2, 'mercapturic acid pathway enzyme': 1, 'omega-6': 1, 'rlip': 2, 'arachidonic acid': 3, 'antineoplastic': 1, 'her2 inhibitors': 1, 'arachidonic acid increased lipid peroxidation': 1, 'rlip inhibitors': 1, 'zm447439': 1, 'hdac inhibitor': 1, 'regular blood transfusion': 1, 'iron': 1, 'antiseizure medications ( antiseizure medications': 1, 'antiseizure medications': 1, 'antiseizure medications should be considered ; cardiac monitoring of treatment': 1, 'embase': 2, 'cinahl': 1, 'carfilzomib': 3, 'proteasome inhibitor': 1, 'chalcone': 2, 'ciprofloxacino': 1, 'ethidium bromide': 1, 'coenzyme q10': 1, 'histopathological': 1, 'ultrastructurally': 1, 'corticosteroids': 1, 'corticosteroid': 13, 'tofacitinib': 1, 'herceptin': 7, 'ferroptosis inhibitor': 1, 'deferoxamine': 1, 'dcfhdaa': 1, 'timedependent': 2, 'glutathione peroxidase ( glutathione peroxidase ) protein expression and the gsh/ gssg ratio in h9c2 cells (wbc in a dose': 1, 'mitofusin': 1, 'selenium plays crucial roles in maintaining the growth and development of vertebrates': 1, 'selenium': 1, 'human': 1, 'synthetic opioids': 1, 'morphine': 1, 'gsh': 1, 'interleukin': 2, 'vegfr': 1, 'bevacizumab': 1, 'immunomodulation': 1, 'sodium chloride solution': 1, 'nicotinic receptor agonist ( pnu : pnu-282987': 1, 'muscarinic receptor agonist ( bet : bethanechol ,': 1, 'alpha7nachr': 2, 'acetylcholine receptors agonists protected': 1, 'caffeic acid phenethyl ester ( caffeic acid phenethyl ester )': 1, 'caffeic acid phenethyl ester': 2, 'caffeic acid phenethyl ester significantly ameliorated': 1, 'mechanistically': 1, 'caffeic acid phenethyl ester attenuated the': 1, 'caffeic acid phenethyl ester significantly enhanced': 1, 'benzofuran': 1, 'chemotypes': 1, 'megestrol': 1, 'megestrol acetate': 1, 'fatty acid oxidation': 1, 'grp78': 1, 'adenosine triphosphate ( adenosine triphosphate )': 1, 'cardiotoxicity': 1, 'radiodensity': 1, 'asparaginase': 1, 'perindopril': 2, 'crispr': 1, 'desipramine': 2, 'proteasome inhibitors such as carfilzomib': 1, 'adenosine triphosphate production': 1}, 'colorectal cancer': {'chemotherapy': 43, 'propofol': 7, 'sevoflurane': 2, 'anesthesia': 2, 'multitesting': 1, 'nctn': 1, 'indole alkaloids': 1, 'diketopiperazines': 1, 'irinotecan': 4, 'conatumumab': 1, 'quercetin': 1, 'fasting insulin': 4, 'fasting insulin ( n = 34 )': 1, 'circulating insulin': 1, 'intratumoral': 2, 'estradiol': 6, 'insulin': 5, 'mir-155_5p': 1, 'ppi': 1, 'nomogram': 3, 'ketamine': 1, 'cox-2': 1, 'microsomal prostaglandin e': 1, 'ptges': 3, 'azoxymethane': 1, 'dextran sodium sulfate': 1, 'mpges-1': 2, 'tatme.linoleic acid ( tatme.linoleic acid )': 1, 'tatme.linoleic acid': 1, 'tatme.linoleic acid treatment': 1, 'tatme.linoleic acid reduced gli2 ubiquitination': 1, 'tatme.linoleic acid - induced cleaved gli2': 1, 'tatme.linoleic acid - mediated suppression of sox17 expression . these results suggest that tatme.linoleic acid promotes tumor cell stemness': 1, 'gli2 fragments via': 1, 'gli2': 2, 'tatme.linoleic acid -': 1, 'antifungal': 1, 'anticancer': 1, 'scfas': 1, 'fluorouracil': 1, 'chemo': 2, 'anticoagulant': 1, 'warfarin': 1, 'sox': 2, 'bevacizumab': 3, 'iris': 1, 'folfiri': 1, 'australasia': 1, 'honokiol': 1, 'lidocaine': 8, 'gemcitabine': 1, 'cisplatin': 1, 'chemotherapy(act)in': 1, 'oxaliplatin': 1, 'analgesia': 8, 'laparotomies': 1, 'interquartile': 1, 'anticoagulants': 1, 'euroqol': 1, 'selenium': 1, 'panitumumab': 1, 'erlotinib': 1, 'gefitinib': 1, 'cellseg': 1, 'ccr6': 1, 'anthraquinone laxatives': 2, 'laxatives': 1, 'wnt ligands': 1, 'porcn inhibitor': 1, '23/174': 1, 'probiotics': 1, 'dihydroartemisinin': 4, 'circrna': 2, 'cochrane library databases': 1, 'nonpharmacologic': 2, 'mesalamine': 2, 'embase': 1, 'cinahl': 1, 'curcumin': 4, 'methotrexate': 5, 'fatty acid synthase ( fatty acid synthase )': 1, 'pelareorep': 1, 'oncolytic': 1, 'reovirus': 1, 'neoadjuvant chemotherapy ( neoadjuvant chemotherapy': 1, 'neoadjuvant chemotherapy': 1, 'overexpression': 1, 'cetuximab': 1, 'transwell': 1, 'bile acid receptor tgr5': 1, 'doublet chemotherapy': 3, 'doublet chemotherapy + anti - epidermal growth factor receptor ( vs doublet chemotherapy': 1, 'aom': 1, 'amino acid': 1, 'doublet chemotherapy immunotherapywith': 1, "peyer 's patches ( peyer's patches": 1, 'tlr6': 1, 'nhsii': 1, 'estrogens': 2}, 'chronic myeloid leukaemia': {'imatinib': 119, 'gleevec': 1, 'haematological': 4, 'asciminib': 1, 'hydroxyurea': 13, 'chemotherapy': 12, 'fludarabine': 3, 'cytarabine': 3, 'ponatinib': 13, 'idarubicin': 1, 'prespecified': 1, 'hypocalcaemia': 1, 'medline': 1, 'embase': 1, 'ruxolitinib': 1, 'lysates': 1, 'tyrosine kinase inhibitors ( tyrosine kinase inhibitors ) and provide optimism to patients with chronic myeloid leukaemia who can look forward to a near - normal life expectancy in a modern tyrosine kinase inhibitors era . background : haematological cancers are clonal diseases of the blood and blood - forming organs , with the distribution pattern not known in our locality . this study aimed to describe the distribution pattern and prevalence of haematological': 1, 'thrombocythaemia': 1, 'dasatinib': 39, 'pharmacokinetics': 2, 'tyrosine kinase inhibitor ( tyrosine kinase inhibitors )': 2, 'nilotinib': 18, '10(6': 1, 'tyrosine kinase inhibitors': 9, 'tyrosine kinase inhibitors before complete cessation is limited . this review highlights the factors predicting success or failure of treatment-free remission . in addition , it examines': 1, 'calcium': 1, 'vitamin d': 1, 'tyrosine kinase inhibitors ( imatinib , dasatinib': 1, 'pkcdelta phosphorylates ikkbeta': 1, 'plcgamma': 2, 'pkcdelta': 1, 'ikkbeta': 1, 'ozawa k': 1, 'szallasi z': 1, 'kazanietz': 1, 'cryptotanshinone': 2, 'azacitidine': 1, 'diuretics': 1, 'steroids': 1, 'hasford': 1, 'tyrosine kinase inhibitors ( tyrosine kinase inhibitors )': 1, 'adriamycin': 3, 'vinblastine': 3, 'dacarbazine': 3, 'interactions': 1, 'flt3 inhibitors': 1, 'tyrosine kinase inhibitors therapy ( > /=1 month ) due to achieving a deep molecular response ( deep molecular response )': 1, 'tyrosine kinase inhibitors treatment duration pre - stop was longer and proportion treated with second - generation tyrosine kinase inhibitors slightly higher outside studies , conceivably affecting the clinical outcome . in summary we show that tyrosine kinase inhibitors': 1, 'c inhibitor': 2, 'collagen': 2, 'agonists': 2, 'epinephrine': 2, 'oncolytic': 1, 'tyrosine kinase inhibitors in an observational prospective study . methods : all consecutive patients affected by chronic myeloid leukaemia and treated with tyrosine kinase inhibitors in our institution were enrolled in the study from february': 1, 'tyrosine kinase inhibitors ( imatinib ,': 1, 'simvastatin': 4, 'mechanistically': 1, 'tyrosine kinase inhibitors therapy against coronavirus disease 2019 in patients with cml.chronic myeloid leukaemia (aml ( chronic myeloid leukaemia )': 1, 'tyrosine kinase inhibitor': 2, 'antibiotic': 3, 'metronidazole': 1, 'chemotherapeutic': 1, 'camkiigamma': 1, 'tyrosine kinase inhibitors dose': 1, 'tyrosine kinase inhibitors after the achievement of major molecular response ( mr3 )': 1, 'tyrosine kinase inhibitors therapy': 1, 'epigenomic': 2, 'deubiquitylating enzyme': 1, 'usp18': 1, 'ribonucleic acid': 1, 'decitabine': 2, 'rapamycin': 2, 'haematopoiesis': 1, 'syngeneic': 1, 'retinoic acid ( retinoic acid': 1, 'retinoic acid - driven functions . introduction : cardiovascular risk factors , pre - existing comorbidities , molecular factors , and the direct effects of second-': 1, 'burkholderiales': 1, 'alcaligenaceae': 1, 'lachnobacterium': 1, 'barnesiellaceae': 1, 'veillonellaceae': 1, 'mitsuokella': 1, 'ponatinib plasma concentration': 1, 'chr22:24701405': 1, 'systemic corticosteroid': 1, 'haematology': 1, 'haemotherapy': 1, 'myelodysplasia': 1, 'osteomyelofibrosis': 1}, 'tumour': {'cytotoxic': 1, 'chemotherapy': 32, 'immunostaining': 1, 'tamoxifen': 16, 'hydroethanolic': 2, 'nitric oxide': 2, 'malondialdehyde': 1, 'glutathione peroxidase ( gsh - px )': 1, 'trichogerminomas': 1, 'alizarin red stainings': 1, 'osteopontin': 1, 'antibiotics': 1, 'clindamycin': 1, 'rifampicin': 6, 'immunohistochemistry': 1, 'chemo': 2, 'octreotide': 2, 'telotristat': 1, 'amplatzer': 1, 'tumourectomy': 1, 'hormonotherapy': 1, 'urothelial': 1, 'arginine methyltransferase': 1, 'fluorouracil': 1, 'peptidyl arginine deiminase': 1, 'imatinib': 1, 'cisplatin': 17, 'agglutinin': 1, 'haematological': 2, 'inflammatories': 1, 'cochrane databases': 1, 'vincristine': 2, 'actinomycin': 2, 'doxorubicin': 5, 'epirubicin': 1, 'ifosfamide': 1, 'carboplatin': 7, 'etoposide': 19, 'cyclophosphamide': 3, 'ccr6': 1, 'embase': 1, 'medline': 1, 'akaike': 1, 'pn': 1, 'tranexamic acid ( tranexamic acid )': 1, 'tranexamic acid': 1, 'tranexamic acid in haematuria': 1, 'polylactic acid filament': 1, 'sugemalimab': 6, 'paclitaxel': 2, 'pemetrexed': 1, 'bleomycin': 3, 'etoposide phosphate': 2, 'hydrocortisone': 1, 'promethazine': 1, 'adrenaline': 1, 'fluids': 1, 'oxygen': 1, 'spironolactone': 6, 'steroid': 4, 'checkpoint inhibitor': 1, 'taxane': 1, 'centre': 1, 'ttk': 2, 'cdc20': 2, 'abiraterone': 1, 'steroids': 1, 'g1': 1, 'characterising': 1, 'multistructure': 1, 'bromelain': 2, 'acetylcysteine': 3, 'gemcitabine': 3, 'chemoimmunotherapy': 1, 'pembrolizumab': 1, 'blockade': 1, 'ctcae': 1, 'nitric oxide ( nitric oxide': 1, 'e)-9': 2, 'raloxifene': 4, 'nephrotoxicity': 1, 'vitamin d': 1, 'vitamin d synthesis': 1, 'vitamin d receptor ( vitamin d receptor )': 1, 'butyrate': 1, 'acetate': 1, 'chemoradiotherapy': 2, 'fondazione': 1, 'gemelli': 1, 'betegeknel': 1, 'gyakran nem lehetseges vagy nehezitette valik': 1, 'gasztroszkop': 1, 'szajon': 1, 'torteno': 1, 'rosszindulatu': 1, 'orv hetil': 2, 'trismus': 1, 'nab - paclitaxel': 1, 'fisetin': 2, 'phf10': 5, 'pyradiomics': 1, 'wilcoxon': 1, 'tumourigenesis': 1, 'nivolumab': 2, 'cabozantinib': 5, 'suvpeak': 2, 'suvapex': 1, 'sorafenib': 3}, 'cancers': {'chemotherapy': 26, 'hdac': 1, 'human histone deacetylase': 1, 'histone': 3, 'deacetylase': 1, 'paeoniaceae': 1, 'cytotoxic': 1, 'antimalarials': 1, 'phosphodiesterase-5 inhibitors': 1, 'neoadjuvant immunotherapy': 1, 'nivolumab': 6, 'ipilimumab': 1, 'indole alkaloids': 1, 'diketopiperazines': 1, 'sargachromenol': 1, 'chemoradiation': 2, 'arsenic trioxide': 1, 'retinoic acid': 2, 'arsenic trioxide combined': 1, 'anthracycline': 2, 'd1': 1, 'd18': 1, 'ductal': 2, 'acinar': 1, 'clonally': 1, 'fasting insulin': 2, 'estradiol': 5, 'insulin': 3, 'paclitaxel': 5, 'heterotypic': 1, 'cox-2': 1, 'microsomal prostaglandin e': 1, 'ptges': 3, 'azoxymethane': 1, 'dextran sodium sulfate': 1, 'mpges-1': 2, 'splc': 1, 'interferon': 1, 'nomogram': 2, 'krippendorff alpha': 2, 'analgesic': 3, 'diclofenac': 7, 'opioid': 1, 'tramadol': 4, 'pain medication': 1, 'cisplatin': 1, 'docetaxel': 1, 'etoposide': 1, 'crispr': 2, 'antifungal': 2, 'anticancer': 1, 'anesthesia': 3, 'cnki': 1, 'wanfang': 1, 'anesthetics': 1, 'progesterone receptor (pr ( progesterone receptor )': 1, 'estrogen receptor': 1, 'unresectable': 1, 'nac': 1, 'braf inhibitors': 2, 'vitamin d supplementation': 1, 'cholesterol biosynthesis': 1, 'epoxidase inhibitors': 1, 'shokat': 1, 'braf': 5, 'her3': 1, 'human monoclonal antibody': 1, 'vemurafenib': 1, 'gamma)153sm': 1, 'physicochemical': 1, 'chemotherapy(tc)and': 1, 'chemo': 9, 'anastrozole': 1, 'bevacizumab': 4, 'fulvestrant)was': 1, 'glucocorticoid': 1, 'trastuzumab': 1, 'immunoblotting': 1, 'intrapleurally': 1, 'cholangiocarcinoma': 1, 'radioactive iodine ( radioiodine ) treatment increased markedly . radioiodine has been associated with an increased risk of leukemia , but risks of second solid malignancies remain unclear . we aimed to quantify risks of second malignancies associated with radioiodine treatment': 1, 'nonsignificantly': 1, 'carboplatin': 3, 'doxorubicin': 1, 'cyclophosphamide': 1, 'nanotherapeutics': 1, 'folate receptor': 1, 'folic acid': 1, 'intratumoral': 1, 'flot': 4, 'steroid': 1, 'thrombospondin': 4, 'radiosensitivity': 1, 'regulate thrombospondin': 1, 'rmats': 1, 'leafcutter': 1, 'ccl8': 1, 'ccl19': 1, 'nucleophosmin': 1, 'homodimerization': 1, 'cochrane databases': 1, 'tsrna': 1, 'cdk4': 1, 'bortezomib': 2}, 'hepatocellular carcinoma': {'heparin sulfate': 1, 'magl': 1, 'chemokine ligand': 1, 'lr': 2, 'monocarboxylate transporter': 1, 'palmitate acid ( palmitate acid': 1, 'palmitate acid - treated aml12 cells': 1, 'sorafenib': 31, 'lenvatinib': 9, 'nod2': 1, 'pyroptosis': 1, 'purine nucleoside monophosphate metabolic process': 1, 'ici': 1, 'clinicopathological': 2, 'adrenergic agonist': 1, 'analgesia': 1, 'sedation': 1, 'chemotherapy': 8, 'cisplatin': 2, 'interactions': 1, 'lysates': 1, '17 k': 1, 'zonula': 2, 'phbx': 2, 'imatinib': 1, 'immunochemotherapy': 1, 'atezolizumab': 4, 'bevacizumab': 4, 'transarterial': 4, 'immunoblotting': 2, 'antihistamines': 3, 'versican': 1, 'maximisation': 2, 'immunohistochemical': 1, 'solamargine': 10, 'anticancer': 4, 'mechanistically': 1, 'tug1': 2, 'hepg2': 1, 'serotonin reuptake inhibitors ( selective serotonin reuptake inhibitors )': 1, 'ssri': 5, 'serotonin reuptake inhibitors': 2, 'carboplatin': 1, 'doxorubicin': 2, 'fluorouracil': 1, 'gemcitabine': 2, '2clibmeca': 1, 'a3arspecific': 1, 'cathelicidin': 1, 'smmc-7721': 1, 'characterising': 1, 'arv': 1, 'galarv': 1, 'fish oil': 3, 'chemoembolization': 1, 'mrnas': 1, "tyrosine kinase inhibitors and/or immunotherapy seem to be the future , depending on the molecular profile of each patient 's tumor . hepatocellular cholangiocarcinoma [cca] ( hepatocellular carcinoma )": 1, 'phenyl benzoate linker in bdp - l - camptothecin': 1, 'camptothecin': 1, 'srting': 1, 'cytoscape': 1, 'ppi': 1, 'chitinase': 4, 'youden': 1, 'free arsenic trioxide ( arsenic trioxide )': 1, 'free arsenic trioxide , arsenic-loaded zeolitic imidazolate framework-8 nanoparticles': 1, 'chemoprotective': 1, 'aspirin': 8, 'cochrane': 1, 'nanocarrier': 1, 'paclitaxel': 6, 'zosuquidar': 4, 'free': 1, 'pro - agiogenic proteins': 1, 'regulate reticulon': 1, 'exo1': 1, 'gadolinium ethoxybenzyl diethylenetriamine penta - acetic acid ( gd - eob - dtpa)-based contrast agent increases its diagnostic value . histologic confirmation is always required': 1, 'antibiotic': 3, 'ceftazidime': 2, 'cefepime': 1, 'oxygen': 1, 'gbms': 1}, 'polycystic ovary syndrome': {'insulin': 78, 'glucose': 10, 'peak insulin': 1, 'fasting insulin': 6, 'analgesics': 1, 'periodontopathogens': 1, 'letrozole': 43, 'adipocytokines': 1, 'curcumin': 12, 'polyphenolic compound': 1, 'curcumin exhibits immobilizing action on sperms , and at': 1, 'chemotherapeutic': 1, 'embase': 3, 'albuminuria': 1, 'hyperandrogenism': 4, 'ivf': 4, 'icsi': 2, 'flutamide': 1, 'spironolactone': 8, 'clomiphene': 3, 'kuntai': 4, 'estradiol': 12, 'berberis': 1, 'berberine': 2, 'dehydroepiandrosterone sulfate': 3, 'luteinizing hormone (lh / follicle - stimulating hormone (lh , testosterone': 2, 'antiandrogen': 2, 'adropin': 1, 'metatrim': 1, 'cholesterol': 1, 'fatty acid (tca oxidation': 1, 'testosterone': 3, 'dehydroepiandrosterone - sulfate ( dehydroepiandrosterone - s )': 1, 'polyunsaturated fatty acids ( polyunsaturated fatty acids )': 1, 'nct04738409.).estradiol': 1, 'steroid': 5, 'erbeta': 1, 'metformin': 51, 'normal saline water ( 0.9': 1, 'malondialdehyde': 4, 'il-6': 1, 'genistein': 4, 'gonadotropins': 1, 'diacerein': 2, 'serum insulin': 1, 'interleukin': 2, 'inflammasome': 1, 'valproate': 1, 'lamotrigine': 2, 'oxcarbazepine': 2, 'carbamazepine': 2, 'progesterone': 11, 'gpx3': 1, 'mrnas': 5, 'tamoxifen': 3, 'clomiphene citrate': 2, 'dehydroepiandrosterone': 6, 'homa - insulin resistance': 1, 'androgens': 2, 'estrogens': 3, 'glucagon': 1, 'peripheral insulin resistance in the early phase of type 2 diabetes . in the skeletal muscle and liver , the atp surplus contributes to insulin resistance': 1, 'donor breastmilk': 1, 'ovarian insulin resistance in polycystic ovary syndrome remain elusive . methods : follicular fluid': 1, 'electroacupuncture': 7, 'indonesia': 1, 'folliculogenesis': 2, 'resveratrol': 5, 'resveratrol potently': 1, 'estrogen': 1, 'phoenixin': 1, 'pnx': 1, 'lipidomic': 1, 'vitamin - like nutrients ( bioflavonoids and alpha - lipoic acid (tca )': 1, 'selenium': 1, 'chromium': 1, 'omega-3 fatty acids': 1, 'probiotics': 4, 'placentaspecific': 2, 'fasting insulin ( fins : wmd -3.40': 1, 'serum metformin concentrations': 1, 'kisspeptin': 1, 'receptor antagonist': 1, 'b analogs': 1, 'vitamin b12': 1, 'vitamin d': 1, 'prebiotics': 2, 'cochrane databases': 1, 'synbiotics': 2, 'pioglitazone': 6, 'ferriman - gallwey score ( f - g )': 1, 'fasting insulin ( fasting insulin': 1, 'genecards': 1, '13,823': 1, 'melatonin': 1, 'glucose transporter ( glut4 )': 1, 'palmitic acid (tca ( physical activity )': 1, 'esr2': 2, 'latvia': 1, 'bile acid (tca and 24 bile acid (tca metabolites': 1, 'taurocholic acid (tca ( taurocholic acid )': 1, 'glycochenodeoxycholic acid (tca ( glycochenodeoxycholic acid )': 1, 'resveratrol possesses anti - inflammatory , antioxidant and antidiabetic properties . the purpose of this study was to evaluate the potential effectiveness of resveratrol in polycystic ovary syndrome based': 1, 'ovariectomy': 1, 'ovulate': 1, 'dysglycemia': 1, 'fasting insulin resistance ( homeostatic model assessment of insulin': 1, 'psychiatric medication': 1, 'statins': 5, 'statin': 1, 'do insulin sensitizing agents such as': 1, 'myoinositol': 3, 'ferriman': 1, 'ferriman gallwey': 2, 'bushen': 3, 'cyproterone': 1, 'norepinephrine': 1, 'hydroxyindoleacetic acid (tca (': 1, 'luteinizing hormone': 1, 'bushen jieyu tiaochong formula': 1, 'atf4': 1, 'drospirenone': 1, 'scopus': 1, 'cochrane': 1, 'orlistat': 2, 'acarbose': 2, 'rosiglitazone': 2, 'sitagliptin': 1, 'lipotoxicity': 1, 'glycerophosphocholines': 1, 'sphingolipids': 1, 'rhamnosus gg': 1, 'free testosterone': 1, 'luteinizing hormone , luteinizing hormone': 1, '17,076': 1, 'antioxidative vitamins ( vitamins )': 1, 'cochrane library databases': 1, 'cinahl': 1, 'pipelle': 1, 'hormone agonist protocol': 2, 'hormone agonist': 1, 'hormone agonist cycles': 1, 'mdm2': 1, 'hyperinsulinism': 1, 'cytoscape': 1, 'ereg': 1, 'wenshentiaojing': 1, 'luteinizing hormone (lh and follicle - stimulating hormone (lh , serum total cholesterol': 1, 'gpr120 agonist decreased insulin resistance in the polycystic ovary syndrome rat model but improved the ovarian function . it is suggested that gpr120 plays a vital role in suppressing insulin resistance , regulating ovary function and decreasing lipid accumulation in the liver , demonstrating that targeting gpr120 could be an effective method for the improvement of pcos.polycystic ovary syndrome (ms ( polycystic ovary syndrome )': 1, 'merck': 2}, 'ypn0': {'neosphere': 2, 'pertuzumab': 14, 'trastuzumab': 42, 'chemotherapy': 234, 'neoadjuvant chemotherapy': 49, 'fluorouracil': 12, 'epirubicin': 39, 'cyclophosphamide': 43, 'docetaxel': 25, 'tryphaena': 1, 'nivolumab': 8, 'neoadjuvant chemotherapy ( neoadjuvant chemotherapy': 4, 'cisplatin': 6, 'perioperative': 2, 'pegylated': 11, 'doxorubicin': 20, 'noninferiority': 1, 'ypt0+ypn0': 1, 'postmastectomy': 46, 'triptorelin': 1, 'concomitantly': 2, 'exemestane': 1, 'capecitabine': 1, 'carboplatin': 35, 'anthracycline': 9, 'clinicopathological': 2, 'neo': 36, 'lapatinib': 1, 'paclitaxel': 39, 'folfox': 2, 'chemoradiation': 12, 'taxane neo-adjuvant chemotherapy': 1, 'neoadjuvant': 22, '14,025': 1, 'nab - paclitaxel ( 260 mg / m(2 ) ) administered intravenously on day 1 in combination with s-1 ( 65 mg / m(2 )': 1, 'nab - paclitaxel': 17, 'nab - paclitaxel combined': 2, 'nab - paclitaxel plus': 2, 'wilcoxon': 1, 'sakk': 1, 'durvalumab': 3, 'chemoradiotherapy': 1, 'leucovorin': 3, 'oxaliplatin': 3, 'irinotecan': 3, 'bevacizumab': 7, 'panitumumab': 3, 'cetuximab': 2, 'folfoxiri': 4, 'cochrane': 1, 'folfirinox': 5, 'germany': 1, 'portugal': 1, 'letrozole': 1, 'tamoxifen': 1, 'neoadjuvant chemoradiotherapy': 1, 'neoadjuvant chemotherapy plus chemoradiotherapy': 1, 'neoadjuvant chemotherapy + chemoradiotherapy': 1, 'neoadjuvant chemotherapy before chemoradiotherapy': 1, 'tch': 1, '46,274': 1, 'calgb': 1, 'eribulin': 2, 'neaodjuvant': 1, 'taxane': 1, 'metformin': 3, 'neoadjuvant nab - paclitaxel improved pathological complete': 1, 'xelox': 1, 'capox': 2, 'embase': 1, 'gemcitabine': 29, 'celgene': 1, 'downstaging': 1, 'pembrolizumab': 7, 'https://clinicaltrials.gov/': 1, 'trimodality': 1, 'neoadjuvant chemotherapy ( neo-adjuvant chemotherapy )': 1, 'sb3': 1, 'dual blockade': 1, 'pcrs': 1, 'nanoparticle albumin - bound paclitaxel ( nab - ptx )': 1, 'folfiri': 1, 'mucositis': 1, 'chemo': 2, 'radiotherapy+/-chemotherapy': 1, 'anthracyclines': 1, 'neoadjuvant pertuzumab': 1, 'nact': 3, 'magseed': 1, 'brpc': 1, 'nab - paclitaxel (': 1, 'nab-paclitaxel ) ( n = 38 ) had significantly improved radiological response according to recist': 1, 'nab-paclitaxel ( n = 38 ) resulted in higher resection rates compared to gem ( 73.3 %': 1, 'nab-paclitaxel': 2, 'clym-': 1, 'estrogen': 1, 'progesterone receptor (pgr status ( odds ratio': 1, 'preoperatively': 1, 'estrogen receptor (pgr - positive ( er+)/human epidermal growth factor receptor (pgr': 1, 'gadolinium': 2, 'beijing': 2, 'estrogen receptor )': 2, 'progesterone receptor (pgr ( progesterone receptor )': 1, 'nonpegylated liposomal': 1, 'normothermic': 2, 'neoajuvant': 1, 'este fue un estudio prospectivo observacional': 1, 'esophagectomy': 1, 'ctnm': 1, 'yptnm': 1, 'beta ( estrogen receptor - beta )': 1}, 'metastasis': {'folfirinox': 1, 'immunoglobulin': 1, 'methylprednisolone': 1, 'photothermal': 4, 'chemokine ligand': 1, 'lr': 1, 'nonadjacent': 1, 'nomogram': 2, 'mineral nanomedicine': 1, 'europium - doped calcium fluoride': 1, 'chemotherapy': 63, 'trifluridine': 3, 'tipiracil': 3, 'ftd': 1, 'fluorouracil': 3, 'oxaliplatin': 7, 'cisplatin': 2, 'irinotecan': 3, 'clinicopathological': 2, 'heparin': 1, 'warfarin': 1, 'vitamin k antagonist': 1, 'anticoagulation': 2, 'isoniazid': 1, 'rifampin': 1, 'premetrexed': 1, 'carboplatin': 1, 'tfeb': 2, 'pn': 2, 'transendothelial': 1, 'mir-155_5p': 1, 'cytoscape': 1, 'cluego': 1, 'palisading': 1, 'histopathological': 1, 'paris saponin': 2, 'nitric oxide synthase': 1, 'suramin': 4, 'suramin compound derivatives synthesized herein show potential as novel therapeutic agents for their anti - proliferative activity via': 1, 'suramin compound': 1, 'ursolic acid ( ursolic acid': 1, 'anticancer': 1, 'ursolic acid': 6, 'tumourectomy': 1, 'hormonotherapy': 1, 'linoleic acid ( linoleic acid': 1, 'linoleic acid': 6, 'linoleic acid reduced gli2': 1, 'linoleic acid - mediated suppression of sox17 expression . these results suggest that linoleic acid promotes tumor cell stemness': 1, 'gli2 fragments via': 1, 'gli2': 2, 'doxorubicin': 1, 'anesthesia': 3, 'cnki': 1, 'wanfang': 1, 'anesthetics': 1, 'progesterone receptor (pr ( progesterone receptor )': 1, 'dimerization blocker , stattic ( s )': 1, 'nanocarrier': 1, 'stattic': 5, 'plga nanoparticles': 1, 'urothelial': 1, 'arginine methyltransferase': 1, "progesterone receptor (pr status . rates of high wilms' tumor 1-associated protein expression were 66.1": 1, 'abemaciclib': 3, 'letrozole': 1, 'steroid': 1, 'prednisolone': 2, 'progesterone receptor': 1, 'fulvestrant': 1, 'ec': 1, 'capecitabine': 2, 'antibiotic': 1, 'nivolumab': 7, 'paclitaxel': 5, 's-1': 1, 'ramucirumab': 2, 'opioids': 1, 'steroids': 1, 'cause(s)and': 1, 'anastrozole': 1, 'leucovorin': 1, 'irinotecan(folfoxiri)plus': 1, 'panitumumab': 1, 'gemcitabine': 1, 'nab - paclitaxel': 1, 'pancreaticoduodenectomy': 1, 'chemoradiotherapy': 1, 'adjuvant chemotherapy': 1, 'folfiri': 2, 'progesterone': 3, 'docetaxel': 1, 'trastuzumab': 3, 'antibiotics': 1, 'bevacizumab': 1, 'cetuximab': 1, 'rhv': 1}, 'pd': {'intratumoral': 1, 'attapulgite': 2, 'pseudogymnoascus': 18, 'exerpd': 2, 'sedpd': 2, 'stereotaxic': 1, 'pemetrexed': 6, 'cisplatin': 3, 'mek inhibitor ( mek inhibitor': 1, 'mek inhibitor / anti - parkinson disease - l1 therapy': 1, 'optn': 1, '28,525': 1, 'pharmacokinetics': 12, 'pharmacodynamics': 4, 'ccl5': 1, 'chemotherapy': 37, 'veronica': 1, 'antifungal': 4, 'stereodivergent': 1, 'stereoinduction': 1, 'carboplatin': 1, 'albumin': 1, 'paclitaxel': 3, 'linezolid': 5, 'rhcl(co)2': 1, 'aucl': 1, 'apomorphine': 2, 'subgingival': 3, 'antibiotic': 2, 'porphyromonas': 2, 'gemella': 1, 'fusobacterium': 1, 'desulfobulbaceae': 1, 'mycoplasmataceae': 1, 'campylobacteraceae': 1, 'muribaculaceae': 1, 'streptococcaceae': 1, 'gemellaceae': 1, 'lactobacillus': 1, 'bifidobacterium': 1, 'megasphaera': 1, 'romboutsia': 1, 'rothia': 1, 'supragingival': 1, 'chemo': 1, 'pembrolizumab': 7, 'methylprednisolone': 1, 'steroids': 1, 'immunosuppressants': 1, 'gepia': 1, 'sd': 2, 'levodopa': 18, 'wilcoxon': 1, 'amantadine': 1, 'selegiline': 1, 'benserazide': 1, 'carbidopa': 1, 'yahr': 1, 'dopamine': 5, 'clinicopathological': 1, 'durvalumab': 7, 'antibiotics': 2, 'clarithromycin': 1, 'ethambutol': 1, 'rifampicin': 1, 'amikacin': 1, 'macrolide': 2, 'methotrexate': 1, 'prednisolone': 1, 'iguratimod': 1, 'dks': 1, 'gemcitabine': 1, 'gammadelta t cells': 1, 'neoadjuvant chemotherapy': 2, 'folfox': 1, 'nivolumab': 6, 'docetaxel(dtx)as': 1, 'capecitabine': 1, 'oxaliplatin': 1, 'nab - paclitaxel plus ramucirumab . the tumor marker levels decreased , the lymph nodes shrank , and pr': 1, 'atezolizumab': 4, 'bevacizumab': 4, 'lenvatinib': 1, 'sorafenib': 1, 'ramucirumab': 1, 'steroid': 1, 'azithromycin': 1, 'oxygen': 1, 'metabolomics': 1, 'mycobiome': 1, 'kazachstania': 1, 'tremellaceae': 1, 'torulaspora': 1, 'mptp': 1, 'multiphysics': 1, 'nanovesicles': 1, 'thrombolytic': 1, 'pentyne': 1, 'desorb': 1, 'azetidines': 1, 'indoles': 1, 'quinolines': 1, 'alloying': 1, 'dextran sulfate sodium': 1, 'functionalized nucleoside analogues': 1, 'histone deacetylase': 3, 'acetic acid ( ph 2.9 )': 1, 'electrogenerated adsorbed hydrogen ( h ads': 1, 'aryl alpha - diazoamides': 1, 'allenes': 1, 'leiws acid': 1, 'carboxylic acid': 1, 'liraglutide': 2, 'mest(high)brca1(high': 1, 'ubiquitin': 1, 'bismuth sulfide nanorods': 1, 'urothelial': 1, 'anesthesia': 2, 'ceftolozane': 1, 'ceftazidime': 1, 'avibactam': 1, 'pmetrics': 1, 'cephalosporins': 1, 'beta - lactamase inhibitors': 1, 'tol': 1, 'electrocatalysis': 1, 'nanocatalyst': 1, 'yangchengdianmao': 1, 'rotenone': 4, 'mogroside v': 2, 'adenosine triphosphate ( adenosine triphosphate ) production in a dose': 1, 'superoxide dismutase': 2}, 'diabetes': {'glucose': 6, 'cochrane llibrary': 1, 'insulin': 30, 'fasting insulin ( fasting insulin': 1, 'fasting insulin ( beta = -1.348': 1, 'fasting insulin': 5, 'hoxy)phenoxy)acetic acid (ara ( lead compound': 1, 'n=63': 1, '1.299': 1, 'apo': 1, 'streptozotocin': 4, 'ferric ammonium citrate ( fac , 200mum )': 1, 'fluoxetine': 6, 'norepinephrine': 1, 'vasopressor': 1, 'carboxyethyl lysine': 1, 'macroalbuminuria': 1, 'linoleic acid (ara ( linoleic acid )': 1, 'arachidonic acid (ara ( arachidonic acid )': 1, 'linoleic acid': 3, 'arachidonic acid': 2, 'linoleic acid - enriched media': 1, 'methylene blue ( methylene blue )': 1, 'nitric oxide synthesis': 1, 'analgesic': 1, 'methylene blue': 2, 'methylene blue group included 53 patients . in both groups , the numeric rating scale': 1, 'methylene blue group were also respective significantly lower than that of the control group at 3 months': 1, 'methylene blue injection': 1, 'methylene blue can significantly reduce pain intensity , improve patient lumbar function , pain - related depression and sleep quality , increase total effective rate with no severe adverse side effects . rapid identification of patients likely': 1, 'allyl isothiocyanate ( allyl isothiocyanate )': 1, 'allyl isothiocyanate': 4, 'allyl isothiocyanate action': 1, 'intragastrically': 1, 'irrespectively': 1, 'allyl isothiocyanate considerably lowered thyroid hormones ( ft4 , ft3 )': 1, 'allyl isothiocyanate at': 2, 'blood insulin': 1, 'chemotherapy': 2, 'fluorouracil': 1, 'leucovorin': 1, 'irinotecan': 5, 'oxaliplatin': 1, 'serine hydrolase carboxylesterase': 1, 'folfirinox': 1, 'anticoagulation': 1, 'statin': 4, 'lysophosphatidylcholines': 2, 'hydroxysphingomyelins': 2, 'acarbose': 1, 'amylase inhibitors': 1, 'vitamin b12': 1, 'glucagon': 10, 'dipeptidyl peptidase 4 inhibitors ( dipeptidyl peptidase 4 inhibitors )': 1, 'acyclic': 2, 'apelin': 1, 'matrix metalloproteinases': 1, 'iron': 1, 'chelation': 1, 'steroids': 1, 'amino acids': 2, 'imidazoles': 1, 'hydroxy acids': 2, 'choline plasmalogens': 1, 'polyunsaturated fatty acids , carotenoids ,': 1, 'nonesterifed fatty acids , phospholipids and carnitines in blood serum using liquid chromatography - tandem mass spectrometry': 1, 'nitric oxide': 2, 'divalent cations ( magnesium , zinc': 1, 'antifungal': 1, 'corticosteroids': 1, 'epithelialization': 1, 'hydroxyproline': 1, 'superoxide dismutase ( superoxide dismutase )': 1, 'glutathione peroxidase ( glutathione peroxidase': 1, 'malondialdehyde': 2, 'antidepressants': 1, 'antipsychotics': 1, 'thymoquinone': 2, 'hyaluronate ( hyaluronate ) group ( n = 30 eyes )': 1, 'hydrocortisone': 1, 'embase': 1, 'amed': 1, 'pregabalin': 3, 'bioactive analogues': 1, 'palmitic acid (ara ( physical activity ) played a synergistic role in the pathogenesis of diabetic peripheral neuropathy . materials and methods : the proliferation rate of rat schwann cell line rsc96 cells': 1, 'fasting insulin ( n = 34 )': 1, 'circulating insulin': 1, 'canagliflozin': 4, 'ovulation': 1, 'letrozole': 11, 'clomiphene citrate': 3, 'clomiphene': 6, 'livebirth': 5, 'takeda': 1, 'roche': 1, 'uric acid , allantoin': 1, 'uric acid': 1, 'red blood cells ( red blood cells': 1, 'high insulin': 1, 'propionate': 1, 'butyrate': 1, 'metformin': 2, 'receptor agonists': 1, 'lifelong insulin': 1, 'rapamycin': 2, 'empagliflozin': 1, 'quercetin': 3, 'vitamin e': 2, 'spectrophotometrically': 1, 'vitamin e treatment reversed these effects , suggestive of their anti - apoptotic effect': 1, 'ighm': 1, 'analgesics': 1, 'leptotricia': 1, 'periodontopathogens': 1, 'antibiotic': 2, 'anesthesia': 1, 'lidocaine': 1, 'propofol': 2, 'rocuronium bromide': 1, 'royal jelly': 1, 'il-2': 1, 'sodium nitroprusside ( sodium nitroprusside': 1, 'oxidative': 1, 'antibiotics': 1, 'corticosteroid': 1, 'scopus': 1, 'machakos': 3, 'sodium ozagrel': 2, 'atorvastatin': 5, 'linagliptin': 1, 'vildagliptin': 3, 'maspin': 4, 'oxygen': 1, 'phosphate buffered saline': 1}, 'ad': {'steroid': 2, 'dexamethasone': 8, 'akt inhibitor reversed neuron-derived neurotrophic factor -': 1, 'thiocholine': 2, 'schisandrae': 2, 'f%': 1, 'ketamine': 1, 'amino acid tryptophan': 1, 'warner - bratzler test': 1, 'hypocholesterolemic': 1, 'vrs': 1, 'canagliflozin': 3, 'amino acids': 1, 'beta-site': 1, 'il-5': 1, 'il-9': 1, 'cladosporium': 1, 'streptozotocin': 4, 'curcumin nanoparticles ( curcumin nanoparticles': 1, 'curcumin': 5, 'nitric oxide ( nitric oxide': 1, 'curcumin nanoparticles': 1, 'generic': 1, 'il-8': 3, 'il-6': 1, 'intracerebroventricular': 1, 'cysteine protease': 1, 'hydroxy - alpha - sanshool liposomes ( hydroxy-alpha-sanshool - lps )': 1, 'hydroxy-alpha-sanshool - lp': 1, 'ad.place': 1, 'vinpocetine': 9, 'ovalbumin': 1, 'asparagine endopeptidase inhibitors': 2, 'asparagine endopeptidase inhibitor': 1, 'embase': 1, 'gst-4': 1, 'dysregulate': 1, 'avicularin': 1, 'fluoxetine': 6, 'sialic acid moiety': 1, 'thiazide': 1, 'diuretics': 1, 'alprazolam': 1, 'nicotine': 1, 'insulin': 2, 'dmso': 1, 'turkey': 1, 'intrahippocampal': 1, 'methanosarcina': 1, 'etoposide': 9, 'hoechst': 1, 'annexin': 1, 'opengrey': 1, 'cannabidiol': 5, 'theaceae': 1, 'stewartieae': 1, 'gordonia': 2, 'schima': 2, 'diapensiaceae': 1, 'pentaphylacaceae': 1, 'styracaceae': 1, 'symplocaceae': 1, 'oligocene': 1, 'amino acid': 2, 'nitric oxide': 2, 'valsartan': 8, 'neprilysin': 1, 'retinoic acid': 5, 'diphenyltetrazolium bromide': 1, 'resveratrol': 7, 'polyphenol antioxidant found in plants': 1, 'jotroltm': 1, 'jotrol': 4, 'neuromodulator norepinephrine': 1, 'physiological saline': 1, 'synbiotics': 3, 'microvascularization': 1, 'immunoblotting': 1, 'aom': 1, 'zinc glycinate': 2, 'zinc glycinate supplementation lowered the average daily': 1, 'fatty acid': 1, 'superoxide dismutase activity': 1, 'nitric oxide synthase inhibitor': 1, 'neuropathogenesis': 1, 'cytotrophoblast': 1, 'corticosteroids': 1, 'gingipains': 1, 'citric acid . contrastingly , lipidomics showed that light - fed animals abundantly gained rhythmicity in levels of triglycerides . furthermore , while the rer shifted entirely with the food intake in the light - fed animals , many measured metabolic parameters ( e.g. , activity and mitochondrial respiration )': 1}}
